INSM
Insmed Incorporated
$106.24
-3.29
(-3.00%)
Mkt Cap
23.03B
Volume
2,432,259
52W Range
65.56-212.75
Sector
Healthcare
Beta
0.89
EPS (TTM)
-5.75
P/E Ratio
-29.12
Revenue (TTM)
819.56M
Rev Growth (5Y)
+29.8%
EPS Growth (5Y)
N/A
Company Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 606.42M | 363.71M | 305.21M | 245.36M | 188.46M | 164.41M | 136.47M | 9.84M | 0 | 0 | 0 | 11.50M |
| Net Income | (1.28B) | (913.77M) | (749.57M) | (481.53M) | (434.65M) | (294.09M) | (254.34M) | (324.28M) | (192.65M) | (176.27M) | (118.18M) | (79.16M) |
| EPS | -6.41 | -5.57 | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | -4.22 | -2.89 | -2.85 | -2.02 | -1.84 |
| Free Cash Flow | (967.58M) | (705.80M) | (549.53M) | (410.32M) | (370.59M) | (226.17M) | (292.92M) | (272.79M) | (162.62M) | (150.91M) | N/A | N/A |
| FCF / Share | -4.53 | -4.30 | -3.91 | -3.33 | -3.31 | -2.32 | -3.46 | -3.55 | -2.44 | -2.44 | N/A | N/A |
| Operating CF | (935.01M) | (683.88M) | (536.25M) | (400.44M) | (363.30M) | (219.35M) | (250.65M) | (257.98M) | (159.62M) | (146.71M) | N/A | N/A |
| Total Assets | 2.26B | 2.03B | 1.33B | 1.66B | 1.24B | 796.15M | 742.30M | 604.56M | 462.05M | 237.96M | N/A | N/A |
| Total Debt | 768.16M | 1.31B | 1.20B | 1.18B | 612.27M | 404.84M | 397.04M | 316.56M | 55.57M | 54.79M | N/A | N/A |
| Cash & Equiv | 510.44M | 555.03M | 482.37M | 1.07B | 716.78M | 532.76M | 487.43M | 495.07M | 381.17M | 162.59M | N/A | N/A |
| Book Value | 738.98M | 285.38M | (331.92M) | 87.95M | 410.47M | 275.88M | 261.67M | 208.27M | 361.06M | 154.48M | N/A | N/A |
| Return on Equity | -1.73 | -3.20 | N/A | -5.48 | -1.06 | -1.07 | -0.97 | -1.56 | -0.53 | -1.14 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 305.96M | 263.84M | 142.34M | 107.42M | 92.82M | 104.44M | 93.42M | 90.34M | 75.50M | 83.69M | 79.07M | 77.23M |
| Net Income | (163.56M) | (328.49M) | (370.02M) | (321.69M) | (256.58M) | (235.55M) | (220.52M) | (300.61M) | (157.09M) | (186.06M) | (158.93M) | (244.81M) |
| EPS | -0.76 | -1.54 | -1.75 | -1.70 | -1.42 | -1.32 | -1.27 | -1.94 | -1.06 | -1.28 | -1.11 | -1.78 |
| Free Cash Flow | (226.22M) | (294.19M) | (222.18M) | (209.05M) | (272.16M) | (202.75M) | (184.60M) | (129.74M) | (188.71M) | (132.97M) | (139.19M) | (127.67M) |
| FCF / Share | -1.05 | -1.38 | -1.05 | -1.10 | -1.50 | -1.13 | -1.06 | -0.84 | -1.27 | -0.92 | -0.97 | -0.93 |
| Operating CF | (222.74M) | (247.60M) | (219.76M) | (205.57M) | (262.09M) | (195.98M) | (180.92M) | (122.95M) | (184.03M) | (130.82M) | (136.33M) | (122.79M) |
| Total Assets | 2.08B | 2.26B | 2.36B | 2.48B | 1.80B | 2.03B | 2.05B | 1.81B | 1.16B | 1.33B | 1.32B | 1.44B |
| Total Debt | 748.43M | 768.16M | 745.08M | 743.34M | 1.31B | 1.31B | 1.16B | 1.38B | 1.37B | 1.36B | 1.20B | 1.19B |
| Cash & Equiv | 582.19M | 510.44M | 334.76M | 1.28B | 403.25M | 555.03M | 461.45M | 1.25B | 595.73M | 482.37M | 487.11M | 612.88M |
| Book Value | 704.85M | 738.98M | 945.57M | 1.25B | 99.16M | 285.38M | 483.42M | 38.82M | (464.81M) | (331.92M) | (289.36M) | (155.75M) |
| Return on Equity | -0.23 | -0.44 | -0.39 | -0.26 | -2.59 | -0.83 | -0.46 | -7.74 | N/A | N/A | N/A | N/A |
INSM News
Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus
Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript
Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish
Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026